Preview Mode Links will not work in preview mode

Feb 8, 2023

Featuring perspectives from Drs Michael Birrer and Kathleen Moore, including the following topics:

  • Gynecologic Oncology  
    • Introduction (0:00)
  • Ovarian Cancer   
    • PARP inhibitors as primary maintenance (8:11)
    • PARP inhibitors for recurrent and metastatic disease (19:04)
    • Antibody-drug conjugates: Mirvetuximab soravtansine; upifitamab rilsodotin (31:39)
  • Endometrial Cancer  
    • Immunotherapy for metastatic disease (43:49)
    • Selinexor as maintenance therapy (51:33)
    • Other novel agents (56:52)
  • Cervical Cancer  
    • Immunotherapy for metastatic disease and the antibody-drug conjugate tisotumab vedotin (1:01:00)

CME information and select publications